BPA Call 36C25723A0033-36C25726N0419
Award Date 8/18/26
Potential Completion Date 8/17/27
Potential Value $701K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Madison, WI 53719, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation for Oncotype DX testing with a ceiling value of $701,268.00, awarded August 18, 2025, with ultimate completion by August 17, 2026. The call is issued under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule. Work is performed in Madison, Wisconsin. Exact Sciences Laboratories, LLC (operating as Exact) will deliver Oncotype DX gene expression profiling assays that...
- Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation under the Medical Laboratory Testing and Analysis Services (FSS-621-II) GSA Schedule on June 5, 2023, with a ceiling value of $31,085.64 for Oncotype DX cancer diagnostic testing services. Performance occurs at Temple, Texas. The call is scheduled for ultimate completion on June 4, 2024. Exact Sciences delivers Oncotype DX gene expression profiling assays that analyze mRNA expression in cancer tumor tissue...
- Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation for Oncotype DX diagnostic testing services with a ceiling value of $17,269.80, awarded June 5, 2024 and completing June 4, 2025. The call is issued under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule. Place of performance is Madison, Wisconsin. The call delivers Oncotype DX gene expression profiling assays, which analyze mRNA expression to assess cancer recurrence...
- <p>Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule on June 5, 2025, with a ceiling value of $52,214.80 and ultimate completion date of June 4, 2026. The call procures Oncotype DX gene expression profiling assays for cancer diagnostic testing. Performance occurs in Madison, Wisconsin. The work is firm fixed price.</p>
- Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation for Oncotype DX testing with a ceiling value of $24,177.72, awarded August 18, 2024, with ultimate completion August 17, 2025. The call is issued under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule. Place of performance is Madison, Wisconsin. The Oncotype DX assay analyzes mRNA expression of specific genes within cancer tumor tissue to assess recurrence risk and...
- Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule on June 5, 2026, with a ceiling value of $52,214.80 for Oncotype DX testing services. Performance is located in Temple, Texas. The call extends through June 4, 2027. The scope covers Oncotype DX gene expression profiling assays for cancer risk assessment and treatment planning across oncology indications. VISN 17...
- Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation for Oncotype breast cancer testing with a ceiling value of $41,447.52, awarded August 18, 2023, with completion August 17, 2024. The call falls under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule. Performance occurs at San Antonio, Texas. The requirement is for Oncotype DX gene expression profiling assays—mRNA expression analysis of cancer tumor tissue to assess...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, has been awarded the execution of Option Year 1 for Oncotype DX testing services to the Department of Veterans Affairs Veterans Integrated Service Network 15. This firm fixed-price Blanket Purchase Agreement (BPA) call, issued without a set-aside designation, carries a ceiling value of $17,769.92 and is scheduled for completion by March 15, 2027. The award was made on March 16, 2026, under the Medical Laboratory...
- Veterans Integrated Service Network 15 issued a BPA call to Exact Sciences Corporation under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule on March 16, 2025, with a ceiling value of $13,815.84 for Oncotype DX testing services. Work is performed at Columbia, Missouri. The call supports base-year testing services for St. Louis VA Medical Center and is firm fixed price. Ultimate completion is scheduled for March 15, 2026. The order incorporates FAR clause...
- This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 15 to Exact Sciences Corporation, Exact Sciences Laboratories, LLC Division, for Oncotype DX testing services. The contract has an ultimate completion date of March 16, 2026 and a ceiling value of $10,442.96. The award is under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule contract. No set-aside designation...
- Medical Laboratory Testing and Analysis Services (FSS-621-II)Master GSA Schedule
- V797D70053-36C25723A0033Blanket Purchase Agreement
- 36C25723A0033-36C25726N0419BPA Call
Veterans Integrated Service Network 17 issued a BPA call to Exact Sciences Corporation for Oncotype DX testing on August 18, 2026, with a ceiling value of $701,268 under the Medical Laboratory Testing and Analysis Services (FSS-621-II) GSA Schedule. The call adds FAR 52.222-90 to an existing agreement and carries an ultimate completion date of August 17, 2027. Work is performed at Exact Sciences Laboratories in Madison, Wisconsin. Exact Sciences provides gene expression profiling assays that analyze mRNA expression in cancer tumor tissue to assess recurrence risk and predict treatment responsiveness across breast, prostate, and colorectal cancers. The call is priced firm fixed-price and carries no set-aside designation.
Generated 6/23/26, 10:37 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $127.2k | 6/21/26 |